inclusion criteria: adults aged 50 years and above at the time of consent subjects who have been confirmed to be covid-19 corresponding to asymptomatic case or mild cases of severity categorization classified by fda through authorized molecular saliva-based test or polymerase chain reaction (pcr) test and who can be available to be administered within 7 days from the onset of any symptoms. patients who provide a voluntarily consent to participate in the study and sign the consent form in his/her own handwriting. female patients of childbearing potential (including female received a tubal ligation) should be prove negative pregnancy through pregnancy test before 24 hours of the ip administration, and must be willing to maintain abstinence (restraint sexual relationships) or use an adequate method of contraception at least 90 days after the ip administration. male patients must be willing to maintain abstinence (restraint sexual relationships) or use of adequate contraception method, and not to donate sperm. men with childbearing or pregnant female spouses should maintain abstinence or use condoms at least 90 days after the ip administration to avoid exposure to embryos patients who agree for the hospitalisation (however, the hospitalisation will be performed only if needed)

inclusion criteria: adults aged 50 years and above at the time of consent subjects who have been confirmed to be covid-19 corresponding to asymptomatic case or mild cases of severity categorization classified by fda through authorized molecular saliva-based test or polymerase chain reaction (pcr) test and who can be available to be administered within 7 days from the onset of any symptoms. patients who provide a voluntarily consent to participate in the study and sign the consent form in his/her own handwriting. female patients of childbearing potential (including female received a tubal ligation) should be prove negative pregnancy through pregnancy test before 24 hours of the ip administration, and must be willing to maintain abstinence (restraint sexual relationships) or use an adequate method of contraception at least 90 days after the ip administration. male patients must be willing to maintain abstinence (restraint sexual relationships) or use of adequate contraception method, and not to donate sperm. men with childbearing or pregnant female spouses should maintain abstinence or use condoms at least 90 days after the ip administration to avoid exposure to embryos patients who agree for the hospitalisation (however, the hospitalisation will be performed only if needed)

inclusion criteria: 1. adults aged 50 years and above at the time of consent 2. subjects who have been confirmed to be covid-19 corresponding to asymptomatic case or mild cases of severity categorization classified by fda through authorized molecular saliva-based test or polymerase chain reaction (pcr) test and who can be available to be administered within 7 days from the onset of any symptoms. 3. patients who provide a voluntarily consent to participate in the study and sign the consent form in his/her own handwriting. 4. female patients of childbearing potential (including female received a tubal ligation) should be prove negative pregnancy through pregnancy test before 24 hours of the ip administration, and must be willing to maintain abstinence (restraint sexual relationships) or use an adequate method of contraception at least 90 days after the ip administration. 5. male patients must be willing to maintain abstinence (restraint sexual relationships) or use of adequate contraception method, and not to donate sperm. men with childbearing or pregnant female spouses should maintain abstinence or use condoms at least 90 days after the ip administration to avoid exposure to embryos 6. patients who agree for the hospitalisation (however, the hospitalisation will be performed only if needed)

inclusion criteria: 1. adults aged 50 years and above at the time of consent 2. subjects who have been confirmed to be covid-19 corresponding to asymptomatic case or mild cases of severity categorization classified by fda through authorized molecular saliva-based test or polymerase chain reaction (pcr) test and who can be available to be administered within 7 days from the onset of any symptoms. 3. patients who provide a voluntarily consent to participate in the study and sign the consent form in his/her own handwriting. 4. female patients of childbearing potential (including female received a tubal ligation) should be prove negative pregnancy through pregnancy test before 24 hours of the ip administration, and must be willing to maintain abstinence (restraint sexual relationships) or use an adequate method of contraception at least 90 days after the ip administration. 5. male patients must be willing to maintain abstinence (restraint sexual relationships) or use of adequate contraception method, and not to donate sperm. men with childbearing or pregnant female spouses should maintain abstinence or use condoms at least 90 days after the ip administration to avoid exposure to embryos 6. patients who agree for the hospitalisation (however, the hospitalisation will be performed only if needed)